Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesEureka AI à l'intérieur
Services professionnels
Témoignages clients
Blog
Rapport mondial sur l'innovation
Glossaire
Newsroom
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Fetal hemoglobin induction, luspatercept expansion, and gene editing in the beta-thalassemia drug pipeline — patent signals, clinical data, and strategic implications.
Article | Rapport Mapping the 2026 optical fiber displacement sensor landscape: four sensing clusters, key assignees, geographic trends, and five emerging directions from patent and literature analysis.
Article | Rapport Explore the AL amyloidosis drug pipeline: daratumumab combinations, birtamimab, CAEL-101, CAR-T, and emerging organ-protection strategies shaping rare disease R&D.
Article | Rapport A 2026 patent and literature landscape of electrochemical bromine recovery: membrane flow cells, battery recycling, flow batteries, and emerging IP signals.
Article | Rapport Fibril clearance antibodies, SAP depletion, and cardiac remodeling approaches in the ATTR cardiac amyloidosis drug pipeline — patent signals and clinical evidence.
Article | Rapport Explore the 2026 photonic QKD technology landscape: key protocols, distance records, chip-scale integration, and strategic IP implications from 20+ years of patent data.
Article | Rapport Photonic QKD has reached 658 km fiber range and 1 Gbit/s key rates. Explore the 2026 technology landscape: protocols, chip integration, and IP white spaces.
Article | Rapport Burosumab expansion, FGF23 pathway inhibitors, and phosphate metabolism approaches shaping the XLH drug pipeline. Evidence from patents and clinical trials.
Article | Rapport Explore the 2026 electrochemical levulinic acid technology landscape: key patents, ECH benchmarks, assignee gaps, and emerging paired electrolysis directions.
Article | Rapport Explore the MCI prevention drug pipeline: BDNF/TrkB signaling, synaptic plasticity, NMDA receptor modulators, and multi-modal approaches targeting pre-dementia cognitive decline.
Article | Rapport A 2026 patent landscape analysis of plasma ozone generation: DBD reactors, AI-controlled systems, plasma vortex, UV-photocatalytic hybrids, and key assignees across Japan, Korea, and Europe.
Article | Rapport Explore the skin aging and photoaging drug pipeline: senolytic topicals, collagen biosynthesis stimulators, and next-generation retinoid approaches. Patent and clinical signals analysed.
Article | Rapport QD-EL device landscape 2026: EQE benchmarks hit 28.7% green, 21.9% blue. Explore patent clusters, assignee data, and emerging directions in QLED technology.
Article | Rapport Survey of the 2026 low-loss dielectric materials landscape for 5G and 6G: polymer substrates, ceramic composites, nano-structures, and key institutional innovators.
Article | Rapport How the NLRP3 inflammasome and IL-6/STAT3 axis are driving a new wave of anti-inflammaging drug development — from MCC950 to senolytics and metabolic repurposing.